# EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.

> **NCT04743453** · PHASE4 · COMPLETED · sponsor: **University of Sao Paulo General Hospital** · enrollment: 211 (actual)

## Conditions studied

- Kidney Transplantation
- Diabetes Mellitus, Type 2
- Diabetes Complications

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04743453
- **Lead sponsor:** University of Sao Paulo General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-17
- **Primary completion:** 2024-09-02
- **Final completion:** 2024-09-02
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2024-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04743453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04743453, "EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04743453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*